department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

when

Latest
Archive

by source

All Sources
Sources Page

by activity

Most Active
Biggest Pipelines
Recently Active

hiring

Companies Hiring Now
Big Pharma Roles
All Companies →

Drugs & Pipeline

intelligence

Drugs
Patent Cliff

research

Publications
Topics

window

Next 90 Days
All (incl. Past)

by type

PDUFAs
Approvals
Earnings
Readouts

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Calendar
Drugs
Companies
News

Hubs

Topics
Jobs
Patent cliff
Publications

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
cal
search

Syndax Pharmaceuticals Inc ($SNDX) · pharmadog

PUBLIC COMPANY

$SNDXSyndax Pharmaceuticals Inc

New York, NY, USupdated 1mo ago

SEC EDGAR ↗Yahoo Finance ↗

community read0 votes

pipeline

2

marketed

1

phase 3

0

catalysts ytd

0

approvals ytd

0

recalls ytd

0

Pipeline(2)

pipeline depth2 products

1Marketed1Unknown

revumenib citrate

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leuk…

1 INDICATIONS AND USAGE REVUFORJ is a menin inhibitor ind…

Upcoming

no upcoming catalysts on record

Recent(90d)

nothing in the last 90 days

view all catalysts →

🐶 Hiring Signal

No open roles indexed yet — view Syndax Pharmaceuticals Inc jobs →

News

no news has mentioned this company yet

identifiers

ticker

$SNDX

SEC CIK

0001395937

country

US

source

sec_tickers

top tags

mentioned in

0news items

entity-linker matched

$SNDX

comments(0)

5-min edit window · permanent after that

sign in to leave a comment · permanent archive after 5 minutes

no comments yet — first sniff?

Data sources

SEC EDGAR · openFDA

last refreshed 33m ago

Found something off?

🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

Active trials

phase1A Study of SNDX-5613 in Combination With Intensive Chemotherapy in Participants With Acute Myeloid Leukemiasactive not recruitingn=76
phase2A Study of Axatilimab at 3 Different Doses in Participants With Chronic Graft Versus Host Disease (cGVHD)recruitingn=296
phase3Study of Revumenib in Combination With Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia (AML) With a NPM1 Mutationrecruitingn=468
phase2MAXPIRe: Study to Evaluate Axatilimab in Participants With Idiopathic Pulmonary Fibrosis (IPF)active not recruitingn=145
phase2A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutationrecruitingn=447
phase2Evaluation of Revumenib in Participants With Colorectal Cancer and Other Solid Tumorscompletedn=42
phase2A Phase 1/2 Study to Evaluate Axatilimab in Participants With Active cGVHDcompletedn=41
—Expanded Access Program for Revumenibno longer available

more trials →

Insider activity

source: SEC Form 4

open-market buys + sells

Feb 9, 26SELLMetzger Michael A· Chief Executive Officer17,159 sh @ $21.03−$361K↗
Feb 9, 26SELLGoldan Keith A.· Chief Financial Officer3,410 sh @ $21.03−$72K↗
Feb 6, 26SELLMetzger Michael A· Chief Executive Officer7,412 sh @ $20.62−$153K↗
Feb 6, 26SELLGoldan Keith A.· Chief Financial Officer2,082 sh @ $20.62−$43K↗

routine RSU / option mechanics (6)

Feb 4, 26grantMetzger Michael A · Chief Executive Officer440,000 sh
Feb 4, 26grantBotwood Nicholas A.J. · Head of R&D, CMO144,700 sh
Feb 4, 26grantGoldan Keith A. · Chief Financial Officer118,000 sh
Feb 4, 26grantBotwood Nicholas A.J. · Head of R&D, CMO36,000 sh
Feb 4, 26grantPodlesak Dennis · director48,000 sh

Feb 4, 26

grant

Rizo Aleksandra · director

24,000 sh